{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:41:35Z","timestamp":1788352895239,"version":"build-2803163510"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computers in Biology and Medicine"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.compbiomed.2022.105565","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T21:17:36Z","timestamp":1651180656000},"page":"105565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["A bibliometric analysis of diffuse large B-cell lymphoma research from 2001 to 2020"],"prefix":"10.1016","volume":"146","author":[{"given":"Junyi","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1730-9322","authenticated-orcid":false,"given":"Wei","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.compbiomed.2022.105565_bib1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ajh.26151","article-title":"Update on Diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management","volume":"96","author":"Susanibar\u2010Adaniya","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"21","key":"10.1016\/j.compbiomed.2022.105565_bib2","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1182\/blood-2017-10-764373","article-title":"Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions","volume":"131","author":"Puente","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.compbiomed.2022.105565_bib4","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41571-019-0225-1","article-title":"Genetic alterations and their clinical implications in DLBCL","volume":"16","author":"Miao","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.compbiomed.2022.105565_bib5","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41571-019-0225-1","article-title":"Genetic alterations and their clinical implications in DLBCL","volume":"16","author":"Miao","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.compbiomed.2022.105565_bib6","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminhematol.2015.01.005","article-title":"The genetic landscape of diffuse large B-cell lymphoma","author":"Pasqualucci","year":"2015","journal-title":"Semin. Hematol."},{"issue":"4","key":"10.1016\/j.compbiomed.2022.105565_bib7","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.17811","article-title":"Molecular profiling in diffuse large B\u2010cell lymphoma: why so many types of subtypes?","volume":"196","author":"Morin","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.compbiomed.2022.105565_bib8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3390\/cancers12010185","article-title":"Molecular complexity of diffuse large B-cell lymphoma: can it Be a roadmap for precision medicine?","volume":"12","author":"Coccaro","year":"2020","journal-title":"Cancers"},{"issue":"25","key":"10.1016\/j.compbiomed.2022.105565_bib9","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1038\/onc.2014.291","article-title":"Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies","volume":"34","author":"Du","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.compbiomed.2022.105565_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eist.2019.01.004","article-title":"An agenda for sustainability transitions research: state of the art and future directions","volume":"31","author":"K\u00f6hler","year":"2019","journal-title":"Environ. Innov. Soc. Transit."},{"key":"10.1016\/j.compbiomed.2022.105565_bib11","series-title":"Bibliometrics and Citation Analysis: from the Science Citation Index to Cybermetrics","author":"De Bellis","year":"2009"},{"issue":"1","key":"10.1016\/j.compbiomed.2022.105565_bib12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/asi.21649","article-title":"A study of the evolution of interdisciplinarity in library and information science: using three bibliometric methods","volume":"63","author":"Chang","year":"2012","journal-title":"J. Am. Soc. Inf. Sci. Technol."},{"issue":"5","key":"10.1016\/j.compbiomed.2022.105565_bib13","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/asi.22645","article-title":"A bibliometric chronicling of library and information science's first hundred years","volume":"63","author":"Larivi\u00e8re","year":"2012","journal-title":"J. Am. Soc. Inf. Sci. Technol."},{"issue":"3","key":"10.1016\/j.compbiomed.2022.105565_bib14","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s11192-015-1762-8","article-title":"Evolution of research subjects in library and information science based on keyword, bibliographical coupling, and co-citation analyses","volume":"105","author":"Chang","year":"2015","journal-title":"Scientometrics"},{"issue":"1","key":"10.1016\/j.compbiomed.2022.105565_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11192-008-1939-5","article-title":"Global stem cell research trend: bibliometric analysis as a tool for mapping of trends from 1991 to 2006","volume":"80","author":"Li","year":"2009","journal-title":"Scientometrics"},{"issue":"6","key":"10.1016\/j.compbiomed.2022.105565_bib16","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/hex.12287","article-title":"Application of multicriteria decision analysis in health care: a systematic review and bibliometric analysis","volume":"18","author":"Adunlin","year":"2015","journal-title":"Health Expect."},{"issue":"3","key":"10.1016\/j.compbiomed.2022.105565_bib17","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/jcm8030360","article-title":"Global evolution of research in artificial intelligence in health and medicine: a bibliometric study","volume":"8","author":"Tran","year":"2019","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.compbiomed.2022.105565_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/opn.12349","article-title":"Global scientific research on social participation of older people from 2000 to 2019: a bibliometric analysis","volume":"16","author":"Fu","year":"2021","journal-title":"Int. J. Older People Nurs."},{"issue":"4","key":"10.1016\/j.compbiomed.2022.105565_bib19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/ijfs9040068","article-title":"The effect of corporate social responsibility on earnings management: bibliometric review","volume":"9","author":"Santos-Ja\u00e9n","year":"2021","journal-title":"Int. J. Financ. Stud."},{"issue":"12","key":"10.1016\/j.compbiomed.2022.105565_bib20","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/buildings11120628","article-title":"Research progress of urban floods under climate change and urbanization: a scientometric analysis","volume":"11","author":"Yang","year":"2021","journal-title":"Buildings"},{"issue":"11","key":"10.1016\/j.compbiomed.2022.105565_bib21","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1002\/asi.23329","article-title":"Growth rates of modern science: a bibliometric analysis based on the number of publications and cited references","volume":"66","author":"Bornmann","year":"2015","journal-title":"Journal of the Association for Information Science Technology"},{"issue":"4","key":"10.1016\/j.compbiomed.2022.105565_bib22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.compbiomed.2022.105565_bib23","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.compbiomed.2022.105565_bib24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.compbiomed.2022.105565_bib25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nm0102-68","article-title":"Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning","volume":"8","author":"Shipp","year":"2002","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.compbiomed.2022.105565_bib26","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1073\/pnas.0500613102","article-title":"Accumulation of miR-155 and BIC RNA in human B cell lymphomas","volume":"102","author":"Eis","year":"2005","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"issue":"18","key":"10.1016\/j.compbiomed.2022.105565_bib27","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.compbiomed.2022.105565_bib28","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor \u03baB activity is required for survival of activated B cell\u2013like diffuse large B cell lymphoma cells","volume":"194","author":"Davis","year":"2001","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.compbiomed.2022.105565_bib29","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J. Exp. Med."},{"issue":"6844","key":"10.1016\/j.compbiomed.2022.105565_bib30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/35085588","article-title":"Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas","volume":"412","author":"Pasqualucci","year":"2001","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.compbiomed.2022.105565_bib31","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1073\/pnas.1732008100","article-title":"A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma","volume":"100","author":"Wright","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.compbiomed.2022.105565_bib3","first-page":"1","article-title":"A potential panel of six-long non-coding RNA signature to improve survival prediction of diffuse large-B-cell lymphoma","volume":"6","author":"Sun","year":"2016","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.compbiomed.2022.105565_bib32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.compbiomed.2022.105565_bib33","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1365-2141.2008.07077.x","article-title":"Detection of elevated levels of tumour\u2010associated microRNAs in serum of patients with diffuse large B\u2010cell lymphoma","volume":"141","author":"Lawrie","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"22","key":"10.1016\/j.compbiomed.2022.105565_bib34","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.compbiomed.2022.105565_bib35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.compbiomed.2022.105565_bib36","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"issue":"7277","key":"10.1016\/j.compbiomed.2022.105565_bib37","first-page":"88","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.compbiomed.2022.105565_bib38","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.compbiomed.2022.105565_bib39","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.compbiomed.2022.105565_bib40","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.compbiomed.2022.105565_bib41","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1073\/pnas.0602266103","article-title":"Pre-B cell proliferation and lymphoblastic leukemia\/high-grade lymphoma in E\u03bc-miR155 transgenic mice","volume":"103","author":"Costinean","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"27","key":"10.1016\/j.compbiomed.2022.105565_bib42","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"1\u20132","key":"10.1016\/j.compbiomed.2022.105565_bib43","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","article-title":"Regulation of ferroptotic cancer cell death by GPX4","volume":"156","author":"Yang","year":"2014","journal-title":"Cell"},{"issue":"7427","key":"10.1016\/j.compbiomed.2022.105565_bib44","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"issue":"7360","key":"10.1016\/j.compbiomed.2022.105565_bib45","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.compbiomed.2022.105565_bib46","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"7332","key":"10.1016\/j.compbiomed.2022.105565_bib47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.compbiomed.2022.105565_bib48","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.compbiomed.2022.105565_bib49","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.1121343109","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","author":"Lohr","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.compbiomed.2022.105565_bib50","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat. Med."},{"issue":"28","key":"10.1016\/j.compbiomed.2022.105565_bib51","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.compbiomed.2022.105565_bib52","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.compbiomed.2022.105565_bib53","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.compbiomed.2022.105565_bib54","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.compbiomed.2022.105565_bib55","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.compbiomed.2022.105565_bib56","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.compbiomed.2022.105565_bib57","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.compbiomed.2022.105565_bib58","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"issue":"16","key":"10.1016\/j.compbiomed.2022.105565_bib59","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.compbiomed.2022.105565_bib60","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.compbiomed.2022.105565_bib61","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.compbiomed.2022.105565_bib62","first-page":"209","article-title":"Gastrointestinal lymphomas: morphology, immunophenotype and molecular features","volume":"3","author":"Bautista-Quach","year":"2012","journal-title":"J. Gastrointest. Oncol."},{"issue":"1","key":"10.1016\/j.compbiomed.2022.105565_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-015-0474-2","article-title":"Novel drug targets for personalized precision medicine in relapsed\/refractory diffuse large B-cell lymphoma: a comprehensive review","volume":"14","author":"Camicia","year":"2015","journal-title":"Mol. Cancer"},{"issue":"1015","key":"10.1016\/j.compbiomed.2022.105565_bib64","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1259\/bjr\/16420165","article-title":"The radiological spectrum of pulmonary lymphoproliferative disease","volume":"85","author":"Hare","year":"2012","journal-title":"Br. J. Radiol."},{"issue":"3","key":"10.1016\/j.compbiomed.2022.105565_bib65","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.blre.2017.12.001","article-title":"The pathobiology of primary testicular diffuse large B-cell lymphoma: implications for novel therapies","volume":"32","author":"Twa","year":"2018","journal-title":"Blood Rev."},{"issue":"7","key":"10.1016\/j.compbiomed.2022.105565_bib67","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2016.151647","article-title":"Genetic background and evolution of relapses in aggressive B-cell lymphomas","volume":"102","author":"Juskevicius","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.compbiomed.2022.105565_bib68","first-page":"10","article-title":"Management of patients with hematologic malignancies during the COVID-19 pandemic: practical considerations and lessons to be learned","author":"Isidori","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.compbiomed.2022.105565_bib69","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jcis.2012.04.051","article-title":"The most frequently cited adsorption research articles in the Science Citation Index (Expanded)","volume":"379","author":"Fu","year":"2012","journal-title":"J. Colloid Interface Sci."},{"issue":"3","key":"10.1016\/j.compbiomed.2022.105565_bib70","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/asi.20317","article-title":"CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature","volume":"57","author":"Chen","year":"2006","journal-title":"J. Am. Soc. Inf. Sci. Technol."},{"issue":"8","key":"10.1016\/j.compbiomed.2022.105565_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254988","article-title":"Trends of global health literacy research (1995\u20132020): analysis of mapping knowledge domains based on citation data mining","volume":"16","author":"Qi","year":"2021","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.compbiomed.2022.105565_bib72","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s11192-010-0202-z","article-title":"The rate of growth in scientific publication and the decline in coverage provided by Science Citation Index","volume":"84","author":"Larsen","year":"2010","journal-title":"Scientometrics"},{"issue":"1","key":"10.1016\/j.compbiomed.2022.105565_bib73","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int. J. Soc. Res. Methodol."},{"issue":"1","key":"10.1016\/j.compbiomed.2022.105565_bib74","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1108\/OIR-03-2018-0068","article-title":"A bibliometric analysis of event detection in social media","volume":"43","author":"Chen","year":"2018","journal-title":"Online Inf. Rev."},{"issue":"1","key":"10.1016\/j.compbiomed.2022.105565_bib75","first-page":"31","article-title":"Pragmatism and self-organization: research collaboration on the individual level","volume":"29","author":"Melin","year":"2000","journal-title":"Science"},{"issue":"44","key":"10.1016\/j.compbiomed.2022.105565_bib76","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7748\/ns.20.44.41.s56","article-title":"Reliability and validity in research","volume":"20","author":"Roberts","year":"2006","journal-title":"Nurs. Stand."},{"issue":"2","key":"10.1016\/j.compbiomed.2022.105565_bib77","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/17538157.2017.1297304","article-title":"Visualization maps for the evolution of research hotspots in the field of regional health information networks","volume":"43","author":"Wang","year":"2018","journal-title":"Inf. Health Soc. Care"}],"container-title":["Computers in Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482522003572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482522003572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T19:52:02Z","timestamp":1757879522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010482522003572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":76,"alternative-id":["S0010482522003572"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiomed.2022.105565","relation":{},"ISSN":["0010-4825"],"issn-type":[{"value":"0010-4825","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A bibliometric analysis of diffuse large B-cell lymphoma research from 2001 to 2020","name":"articletitle","label":"Article Title"},{"value":"Computers in Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiomed.2022.105565","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105565"}}